Set to open by the end of 2021, the new facility will provide testing services to help pharmaceutical, biopharmaceutical and medical device customers in the Southeast Asian market to verify product safety.
India has emerged as a leader in biopharmaceutical manufacturing, and the market is expected to grow in revenue from USD 41.7 billion in 2020 to USD 130 billion by 2030, at a CAGR of approximately 12%.
With approximately 3,000 sq. ft. of space, the new extension to our Navi Mumbai facility will be uniquely positioned to meet the growing needs of the market. It will offer a broad spectrum of the latest E&L testing solutions, such as:
- GC-MS and HS-GCMS for the analysis of semi-volatile and volatile components
- LC-MSMS for the quantitative analysis of trace leachable components
- HR-LC-MSMS to generate data that supports the identification of unknown components
- ICP-MS to quantitate screening and identification of inorganics
This investment in top-of-the-line testing capabilities, such as the Orbitrap mass HR-LC-MSMS technology, positions SGS at the forefront of the E&L segment, setting the standard for other providers in the market.
The laboratory in India will complement SGS's existing testing network, with three other E&L centers of excellence located in the US, Germany and China. Thanks to strategic collaboration between our different sites, we can better support our global clients in verifying their products' safety.
Our extensive range of testing solutions allow us to offer tailored solutions for a wide variety of pharmaceutical, biopharmaceutical and medical device products that meet international quality standards.
For your information, please contact:
Head of Laboratories
t: +91 22 6457 2540
We are SGS – the world’s leading testing, inspection and certification company. We are recognized as the global benchmark for quality and integrity. Our 93,000 employees operate a network of 2,600 offices and laboratories, working together to enable a better, safer and more interconnected world.